Today@Dal

Pneumococcus bacteria causes various diseases with significant impacts, such as pneumonia and meningitis. Pneumococcal conjugate vaccines (PCVs) increase protection against 10, 13, or 20 varieties (or serotypes). But there are over 100 kinds of pneumococcus and PCVs don’t yet cover some important serotypes that remain threats. A new vaccine against more serotypes could improve child health and survival globally. 

An early-stage Phase 1/2 clinical study at the Canadian Center for Vaccinology will evaluate a new PCV designed to cover 25 serotypes of pneumococcus posing greatest risk to children globally, but particularly in low- and middle-income regions where the pneumococcal disease burden is highest. 

Are you 18-40, in good health, and have not received a Pneumoccocal Conjugate Vaccine (PCV)? Learn more about participation here: https://bit.ly/3Rwi42I

Or contact Krystal Lariviere at 902-470-8141 or ccfv@iwk.nshealth.ca